Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Kortuem

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Onkologie|May 27, 2010
Lenalidomide-induced hypersensitivity pneumonitisMartin Kortuem, Hermann Einsele
Blood|February 9, 2013
CarfilzomibK Martin Kortuem, A Keith Stewart
Leukemia & Lymphoma|September 13, 2012
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myelomaYuan Xiao Zhu, K Martin Kortuem, A Keith Stewart
Hematology/Oncology Clinics of North America|January 10, 2024
Bispecific Antibodies in the Treatment of Multiple MyelomaXiang Zhou, Xianghui Xiao, Klaus Martin Kortuem, et al.
Presse Medicale (Paris, France : 1983)|December 11, 2024
Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: Where do we stand today?Xiang Zhou, K Martin Kortuem, Leo Rasche, et al.
Diseases of the Colon and Rectum|April 7, 2006
Morbidity of temporary loop ileostomy in patients with colorectal cancerAndreas Thalheimer, Marco Bueter, Martin Kortuem, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 26, 2014
Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myelomaK Martin Kortuem, Kaitlyn Zidich, Steven R Schuster, et al.
Investigative Radiology|July 17, 2025
Whole-body Dual-source Photon-counting CT in Multiple Myeloma-The Value of Virtual Monoenergetic Imaging for Lesion Vitality AssessmentAnke Heidemeier, Henner Huflage, Leo Rasche, et al.
Blood|November 15, 2014
RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2Yuan Xiao Zhu, Hongwei Yin, Laura A Bruins, et al.
European Journal of Radiology|August 26, 2022
Multi-parametric whole-body MRI evaluation discerns vital from non-vital multiple myeloma lesions as validated by <sup>18</sup>F-FDG and <sup>11</sup>C-methionine PET/CTAnke Heidemeier, Wiebke Schloetelburg, Annette Thurner, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Onkologie|May 27, 2010
Lenalidomide-induced hypersensitivity pneumonitisMartin Kortuem, Hermann Einsele
Blood|February 9, 2013
CarfilzomibK Martin Kortuem, A Keith Stewart
Leukemia & Lymphoma|September 13, 2012
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myelomaYuan Xiao Zhu, K Martin Kortuem, A Keith Stewart
Hematology/Oncology Clinics of North America|January 10, 2024
Bispecific Antibodies in the Treatment of Multiple MyelomaXiang Zhou, Xianghui Xiao, Klaus Martin Kortuem, et al.
Presse Medicale (Paris, France : 1983)|December 11, 2024
Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: Where do we stand today?Xiang Zhou, K Martin Kortuem, Leo Rasche, et al.
Diseases of the Colon and Rectum|April 7, 2006
Morbidity of temporary loop ileostomy in patients with colorectal cancerAndreas Thalheimer, Marco Bueter, Martin Kortuem, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 26, 2014
Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myelomaK Martin Kortuem, Kaitlyn Zidich, Steven R Schuster, et al.
Investigative Radiology|July 17, 2025
Whole-body Dual-source Photon-counting CT in Multiple Myeloma-The Value of Virtual Monoenergetic Imaging for Lesion Vitality AssessmentAnke Heidemeier, Henner Huflage, Leo Rasche, et al.
Blood|November 15, 2014
RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2Yuan Xiao Zhu, Hongwei Yin, Laura A Bruins, et al.
European Journal of Radiology|August 26, 2022
Multi-parametric whole-body MRI evaluation discerns vital from non-vital multiple myeloma lesions as validated by <sup>18</sup>F-FDG and <sup>11</sup>C-methionine PET/CTAnke Heidemeier, Wiebke Schloetelburg, Annette Thurner, et al.
Pageof 2